Market News AIOpen the app

BMRN stock news · BioMarin Pharmaceutical Inc.

Stories about BioMarin Pharmaceutical Inc. (BMRN) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for BMRN

Follow BioMarin Pharmaceutical Inc. (BMRN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BMRN
Free on the App Store and Google Play, or on the web.
  1. Oct 6, 2026, 4:30 PM ET · Market

    BioMarin Pharmaceutical Inc. shares how its business is doing after buying Alesta Therapeutics.

    Bad for BMRN

    BioMarin expects Alesta acquisition costs to lower 2026 profit, and the filing gives no expected sales or clinical results to balance that hit. This is unfavorable for BMRN.

  2. Sep 14, 2026, 10:12 AM ET · Market

    BioMarin Pharmaceutical Inc. is adding Dr. Robert Plenge to its Board of Directors starting September 10, 2026.

    Neutral

    BioMarin added Dr. Plenge to its board and Science and Technology Committee with a $400,000 RSU grant.

  3. Aug 18, 2026, 1:52 PM ET · Market

    BioMarin aims to bolster its presence in the treatment of rare bone diseases.

    Good for BMRN

    BioMarin's acquisition of Alesta Therapeutics for $275 million, with potential additional payments, positions the company to enhance its offerings in the rare bone disease market. This strategic move is expected to provide long-term value, especially as it aims to compete with existing therapies like AstraZeneca's Strensiq.